Company intelligence / Profile preview
Triphase Accelerator
Toronto, Ontario, Canadaprweb.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
TRPH‑222 showed positive updated Phase 1 data in relapsed/refractory B-cell non-Hodgkin’s lymphoma with an overall response rate of ~54%, complete response rate of ~38%, median duration of response ~25 months, and favorable safety profile. Marizomib was advanced to Phase 3 by Celgene after acquisition.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugates (ADCs)Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Celgene Corporation/Bristol Myers Squibb – multiple oncology collaborations including option/acquisition deals for pipeline assets such as marizomib and TRPH‑395Catalent Biologics for ADC technology licensingOntario Institute for Cancer Research, MaRS Innovation/FACIT/TIAP as founding partners/funders.
Beyond the preview
Go deeper on Triphase Accelerator.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triphase Accelerator.